| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer
1 company
Hohl Benjamin is a Chief Financial Officer at Enliven Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 14 sells.
Estimated insider holdings value: $1.6M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $20.41 | $66,326.98 | -20.0% | -20.2% | +47.3% | |
| Feb 5, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,000 | $22.52 | $22,524.40 | -7.1% | -13.5% | +18.6% | |
| Jan 27, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $21.59 | $70,177.90 | -20.0% | -11.2% | +22.9% | |
| Jan 3, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,000 | $25.04 | $25,038.60 | -7.1% | -18.0% | -36.4% | |
| Dec 30, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 4,250 | $22.23 | $94,474.41 | -100% | -12.1% | -30.5% | |
| Nov 27, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 5,250 | $24.89 | $130,688.38 | -84.0% | -20.8% | -15.0% | |
| Oct 28, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 6,250 | $28.56 | $178,484.63 | -90.6% | -25.7% | -24.8% | |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 814 | $30.00 | $24,422.44 | -100% | -24.2% | -26.2% | |
| Oct 7, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 11,488 | $27.51 | $316,014.07 | -100% | -12.3% | -26.7% | |
| Oct 1, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 521 | $27.54 | $14,346.88 | -100% | -13.9% | -23.8% |